Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GMABBullishIndustry Newsnews

High materiality7/10

Genmab's Rina-S achieves 45.9% ORR in PROC, potential Phase 3 upside

Oct 3, 2026, 3:51 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Robust ORR, durable responses, and FRα-agnostic activity raise confidence in Rina-S’s clinical benefit and support multiple Phase 3 catalysts, likely aiding GMAB's valuation if Phase 3 results are favorable or positive read-through.

AI summary

What happened, with direct paths to the underlying reporting

Genmab's Rina-S in platinum-resistant ovarian cancer demonstrated a 45.9% confirmed ORR among 109 patients (Part C of RAINFOL-01), with a median DOR of 12.1 months and median PFS of 9.5 months. Importantly, activity was observed across FRα expression levels, including low/non-expressors, supporting broad patient applicability and strengthening Phase 3 RAINFOL-02/03/04/07 read-through and potential valuation impact.

RAINFOL-01 Part C: ORR 45.9% in 109 PROC patients.
mDOR 12.1 months; mPFS 9.5 months.
Activity across FRα expression, incl. low/non-expressors.
No ocular toxicity or major safety signals; SAEs ~33%.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Genmab's Rina-S achieves 45.9% ORR in PROC, potential Phase 3 upside

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

Genmab's blood cancer drug fails main goal in late-stage study

Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets

Genmab scraps development of experimental cancer therapy